canakinumab
Novartis
['lung']
no clear signals in the subgroup analysis. survival shown here (exploratory) and fewer events overall than expected. lung cancer specific mortality similar between both arms. rates of aes also similar between two arms. #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him